Skip to main content

Table 1 Blood pressure, heart rate and metabolic parameters

From: AT1-receptor-deficiency induced atheroprotection in diabetic mice is partially mediated via PPARγ

 

Total cholesterol (mmol/l)

Fasting blood glucose (mmol/l)

Change in body weight (%)

Systolic BP (mmHg)

Heart rate (beats/min)

Diabetic ApoE−/−

     

Vehicle (n = 8)

29 ± 3*,#

23 ± 1*,#

−5,2 ± 0.5*,#

124 ± 4#

992 ± 32*

Telmisartan (n = 8)

31 ± 5*

19 ± 1*

−6,9 ± 0.3*

132 ± 9

710 ± 91

Telmi + GW9662 (n = 7)

48 ± 7*‡

22 ± 0.5*

−3.4 ± 0.6*

124 ± 5

887 ± 66*

GW9662 (n = 7)

72 ± 12*,#,‡

32 ± 1*,#,‡

−12.4 ± 0.6*,#,‡

123 ± 7#

1040 ± 55*,#

Diabetic ApoE/AT1−/−

     

Vehicle (n = 6)

15 ± 5*

12 ± 1*

12.6 ± 0.7*

106 ± 2

884 ± 70

GW9662 (n = 6)

17 ± 3*

19 ± 2*,#

−5.9 ± 0.9*,#

106 ± 4

772 ± 38

Non-diabetic ApoE−/−

     

Vehicle (n = 8)

20 ± 2

5 ± 0.2

46 ± 0.8

123 ± 3

649 ± 38

Telmisartan (n = 8)

21 ± 3

5 ± 0.4

40 ± 0.3

118 ± 4

727 ± 21

Telmi + GW9662 (n = 8)

22 ± 2

5 ± 0.3

42 ± 0.5

125 ± 4

708 ± 42

GW9662 (n = 8)

18 ± 1

4 ± 0.4

48 ± 0.3

131 ± 3

695 ± 13

Non-diabetic ApoE/AT1−/−

     

Vehicle (n = 6)

8 ± 3

5 ± 1

47 ± 0.6

102 ± 5*

742 ± 46

GW9662 (n = 6)

8 ± 3

4 ± 1

50 ± 0.5

105 ± 5*

679 ± 50

  1. To determine cardio-metabolic effects systolic BP, heart rate, fasting blood glucose levels, change in body weight and total cholesterol levels were assessed in vehicle treated diabetic and non-diabetic ApoE−/− and ApoE−/−/AT1R−/−-mice. *P < 0.05 vs. non-diabetic groups. #p < 0.05 vs. corresponding diabetic ApoE−/−/AT1R−/−. P < 0.05 vs. vehicle treated diabetic ApoE−/−, n = 6-8 per group.